发明名称 |
HUMAN IMMUNODEFICIENCY VIRUS ENTRY INHIBITOR ASSAY |
摘要 |
The present invention is a method for evaluating the ability of a compound to prevent the Human Immunodeficiency Virus ("HIV") from entering into a T cell. The method involves fusing a first cell line that mimics HIV viral particles by expressing a gpl20-gp41 complex on the cell surface and that contains a Tat protein in the cytoplasm with a second cell line that mimics T cells by expressing CD4 and its co- receptors on the cell surface and that contains a Tat-inducible reporter gene expression cassette in the nucleus. The cell lines are fused alone or in the presence of a potential HIV entry inhibitor and the amount of beta-galactosidase produced by the fused cells is determined. Compounds that reduce the amount of beta-galactosidase produced by the fused cells have interfered with the interaction of the gpl20-gp41 complex and CD4 and its co-receptors and are therefore deemed be HIV entry inhibitors.
|
申请公布号 |
KR20060130557(A) |
申请公布日期 |
2006.12.19 |
申请号 |
KR20067009029 |
申请日期 |
2006.05.10 |
申请人 |
TANOX INC. |
发明人 |
ZOU LINGLONG;LIU MENG YUAN |
分类号 |
C07K16/00;C07K;C07K16/08;C12Q1/70;G01N33/50;G01N33/53;G01N33/536;G01N33/569;G01N33/574 |
主分类号 |
C07K16/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|